Kornimate/medical-research-clean huggingface dataset:
evaluation of patients with knee osteoarthritis receiving a prosthesis

Conditions: Osteoarthritis, Knee; Perfusion; Bone Marrow; Magnetic Resonance Imaging

Summary: patients with osteoarthritis of the knee undergo visible joint changes in radiology and magnetic resonance imaging (mri) tests, but also clinically and histologically. the area of greatest change is at the subchondral/cartilage bone junction. investigators will determine the association between preoperative clinical evaluation (ikdc and womac scores), radiological classifications and histopathology. in addition, the role of inflammation in the pathogenesis of osteoarthritis is being given major interest, and inflammation is closely linked with vascularization. it was recently demonstrated that dynamic contrast-enhanced magnetic resonance imaging (dce-mri) could identify the subchondral bone marrow vascularization changes occurring in osteoarthritis in animals. these changes appeared before cartilage lesions were visible and were correlated with osteoarthritis severity. thus the opportunity to obtain an objective assessment of bone vascularization in non-invasive conditions in humans might help better understanding osteoarthritis pathophysiology and finding new biomarkers. investigators hypothesized that, as in animals, dce-mri has the ability to identify subchondral bone marrow vascularization changes in human osteoarthritis.


Eligibility criteria:
inclusion criteria: * patients with knee osteoarthritis, classified kellgren-lawrence 3 or 4, with asymmetric femorotibial joint space narrowing * patients requiring a total knee prosthesis exclusion criteria: * patients with a known progressive inflammatory pathology (rheumatoid arthritis,...). * patients with previous surgery of the knee * contra-indication for magnetic resonance imaging, chronic renal failure (creatinine clearance \< 30 ml/min), contrast media allergy, orthopaedic hardware around the knee. patients in whom motion artifacts impaired image analysis will be excluded.

Keywords: osteoarthritis knee bone bone marrow magnetic resonance imaging
a phase 3 clinical trial to evaluate the efficacy and safety of [18f]nav4694 pet for detection of cerebral beta-amyloid when compared with postmortem histopathology

Conditions: Dementia; Alzheimer's Disease

Summary: to determine the the efficacy and safety of \[18f\]nav4694 pet for detection of cerebral β-amyloid when compared with postmortem histopathology


Eligibility criteria:
inclusion criteria: * male or female subjects will be at least 21 years of age. * subjects will have a life expectancy of approximately 6 months * subject health is adequate as determined by the investigator to receive \[18f\]nav4694 * female subjects will not be of child-bearing potential or will have a negative urine pregnancy test on day of \[18f\]nav4694 injection. * must exhibit adequate visual, auditory, and communication capabilities to enable compliance with study procedures. this includes being able to lie down flat in the mri or ct and pet scanner for a period of approximately 1 hour. * subjects must be willing to donate their brains for post mortem examination upon death (this consent can be obtained in the manner specific to the country/region involved). * subjects have been fully informed about the study, including provisions of the health insurance portability and accountability act (hipaa), as applicable, and informed consent or assent has been signed and dated (with time) by the subject and/or the subject's legally acceptable representative (lar) (for individuals with dementia). exclusion criteria: * scheduled for surgery and/or another invasive procedure within the time period of up to 7 days after \[18f\]nav4694 injection. * has severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumor (metastasis/brain cancer) as verified by mri that prohibits sampling of the required pre-specified rois. * has any history of any transmissible spongiform encephalopathy (prion disease). * has received any contrast material (x-ray, mri) or radiopharmaceutical within 48 hours prior to, or a therapeutic radiopharmaceutical (e.g., 131-i) within 10 days prior to, or any radiopharmaceutical administration within 10 radioactive half-lives prior to the administration of the investigational product or for whom administration of such substances is planned within 7 days after investigational product administration. * is allergic to the investigational product or any of its constituents.

Keywords: dementia alzheimer's disease terminally ill
the antiseptic efficacy and tolerability of lavasept® 0.04% on acute traumatic wounds

Conditions: Wounds

Summary: the primary objective of the study is to assess the antiseptic efficacy of lavasept 0.04% when used as an antiseptic agent and to compare these with ringers' solution in patients with acute traumatic wounds.


Eligibility criteria:
inclusion criteria: * patients with acute traumatic cut, crush, abrasion, bite or stab wounds provision of voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the institutional ethics committee (iec) prior to all evaluations * wounds that are a minimum of approximately 4 cm2 in size * ability to read and understand the german patient information sheet and informed consent form exclusion criteria: * \< 18 years of age * pregnancy * immunosuppression * wounds caused by a burn * wounds that require treatment of hyaline cartilage, the central nervous system, peritoneum, meningae, inner / middle ear or inner eye * simultaneous participation in another clinical trial * wounds that require immediate surgical or medical treatment as well patients who are critically ill * patient with a known allergy to the active agent or any of the excipients * wounds that are \>3 cm in depth * wounds that have not received medical treatment for ≥6 hours * heavily bleeding wounds * open fractures, joints or tendons * wounds of the face

Keywords: acute traumatic wounds
the factors affecting adr of screening colonoscopy

Conditions: Adenoma Detection Rate; Colonoscopy

Summary: the purpose of this study is to assess the impact of multilevel factors on the quality of screening colonoscopy, reflected mainly by adenoma detection rate (adr).

the subjects will include patients who need to screening colonoscopies by 21 endoscopists between january 2019 and december 2019 were retrospectively enrolled in this unit. multilevel factors, including patient-, proceduralist-, and procedure-level characteristics were analyzed for the relationship with adr.

Eligibility criteria:
inclusion criteria: * patients were retrospectively included in this study if they had undergone a completed colonoscopy. exclusion criteria: * prior colonoscopy within 3 years; * medical history of inflammatory bowel disease (ibd), crc, or abdominal surgery; * fair or poor quality of bowel preparation (fair quality: some semisolid stool that could be suctioned or washed away but \>90% of mucosal surface seen; poor quality: semisolid stool that could not be suctioned or washed away with \<90% of mucosal surface seen); * failure in cecal intubation; * withdrawal time without removing\<6 min.
innovating technology solutions for residents in support housing communities w sud through community-engaged research

Conditions: Housing Problems; Household Substance Abuse; Substance Use Disorders; Harm Reduction

Summary: the goal of this clinical trial is to understand whether a technology-based solution, provided to residents in permanent supportive housing, is acceptable, feasible to implement, and has promise for improving resident stability. the main questions it aims to answer are: • is the technology-based, community-defined solution usable, acceptable, feasible, and have promise of effectiveness for improving resident knowledge? there is no comparison group, all participants will receive the technology-based intervention. researchers expect the intervention will include 2 weeks of intervention content that includes videos and incentives for completing content though the solution tested will ultimately be co-defined by our community board.

our clinical trial is a pre-post assessment of resident knowledge.

Eligibility criteria:
residents: 1. 18 and older; 2. past or current resident in supportive housing community; 3. past or current elevated substance use staff: 1. 18 or older; 2. staff at partner agency

Keywords: eviction, housing stability, training
brain stimulation and meditation for pain after total knee arthroplasty

Conditions: Osteoarthritis, Knee

Summary: feasibility, acceptability, and preliminary efficacy of combined transcranial direct current stimulation and mindfulness for pain after total knee arthroplasty

the project is to assess the preliminary feasibility, acceptability, and efficacy of self-administered preoperative tdcs+mbi in older adults (50+) undergoing tkr. and to determine the effects of 5, 20-minute preoperative self-administered tdcs sessions combined with brief mbi on analgesic medication consumption following tkr.

Eligibility criteria:
inclusion criteria: * elective unilateral knee total replacement * mentally capable of reading, giving consent and following instructions * being able to answer questions in english * not pregnant exclusion criteria: * history of brain surgery, brain tumor, seizure, stroke, or intracranial metal implantation * systemic rheumatic disorders, including rheumatoid arthritis, systemic lupus erythematosus, and fibromyalgia * alcohol/substance abuse * current use of sodium channel blockers, calcium channel blockers and nmds receptor antagonists * hospitalization within the preceding year for psychiatric illness * no access to a device with internet access that can be used for secure videoconferencing for real-time remote supervision
pilot-study for the comparison of biomarkers between regular cannabis users and non-users

Conditions: Driving Under the Influence of Cannabis

Summary: the relevance of driving under the influence of cannabis is becoming increasingly important in the context of legalization. however, the measurement of tetrahydrocannabinol (thc) blood concentration is an inadequate marker for assessing driving impairment. currently, there is no reliable marker available for estimating the time of last cannabis inhalation, which would provide a promising tool for regulating driving under the influence of cannabis. this pilot study aims to explore potential biomarkers and factors that could approximate the timing of the last cannabis inhalation, with emphasis on the potential explanation of interindividual differences in thc pharmacokinetics and -dynamics. the results will assist future research aimed at improving the ability to distinguish between impaired and unimpaired cannabis users in road traffic. these findings are of significant importance for road safety and for society at large, as they may provide more objective markers for cannabis inhalation, thereby permitting a methodologically sound evaluation of driving under the influence of cannabis.


Eligibility criteria:
inclusion criteria: * experience of smoking cannabis products, on average once a week. this may be in combination with tobacco. * age 18-65 years possession of driving license in at least one of the categories a, b, a1; b1, f, g or m * sufficient knowledge of german * no cannabis inhalation or nicotine consumption on study day * no alcohol consumption within the last 24 h exclusion criteria: * participation in a trial with investigational drugs within 30 days * current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder) * pregnancy or breastfeeding * intake of cyp2c9, cyp2c19, and cyp3a4-inducers in the last 4 weeks before the study visit, e.g. rifampicin (antibiotic), carbamazepine (anticonvulsant), phenobarbital (anticonvulsant), phenytoin (anticonvulsant) or inhibitors, such as amiodarone (class iii antiarrhythmic medication), antifungal drugs such as fluconazole, miconazole, voriconazole and itraconazole, antibiotics such as clarithromycin and sulfamethoxazole, ritonavir (protease inhibitor) and grapefruit juice. * the following conditions: vasopressin deficiency, pituitary tumor, active malignancy, severe hyponatremia requiring treatment, congestive heart failure, liver cirrhosis.

Keywords: cannabis driving biomarker
the effect of asymmetric spinal stabilization exercise on scoliosis

Conditions: Scoliosis Idiopathic

Summary: the purpose of this study is to evaluate the effect of asymmetric spinal stabilization exercise on scoliosis

* design: prospective study * setting: hospital rehabilitation department * intervention: participants are educated asymmetric spinal stabilization exercise along scoliosis curve patterns, including the location of apex and the direction of convexity. after performing asymmetric spinal stabilization exercise, participants are compared the main outcome measures. * main outcome measures: cobb angle, apical vertebral rotation in adam's test, surface emg, scoliosis research society-22(srs-22) quastionnaire

Eligibility criteria:
inclusion criteria: * who have idiopathic scoliosis, showing at cobb's angle over 10 degrees on x-ray exclusion criteria: * patients who underwent spinal surgery * patients with spinal scoliosis due to cerebral palsy, muscle paralysis, polio, congenital spinal abnormalities * patients observed with cobb's angle less than 10 degrees, over 40 degrees * patients complaining of acute low back pain

Keywords: surface emg cobb angle exercise spinal curvatures
pazopanib in patients with progressive recurrent and/or metastatic salivary gland carcinoma

Conditions: Salivary Gland Carcinoma

Summary: open-label, multicenter, single arm phase ii study, set up in collaboration with the "réseau d'expertise français sur les cancers orl rares" (refcor), evaluating the activity and safety of single agent pazopanib in recurrent or metastatic tumors in salivary gland including adenoid cystic carcinoma (acc) and to exploring the activity and safety of pazopanib in non-adenoid cystic carcinoma (non-acc).

in the non-acc sgchn population, assessment of the activity of pazopanib is exploratory without a predetermined study design, with up to 20 patients. a planned interim analysis of acute toxicities was conducted 3 months after the 14th non-acc inclusion. acc as the endpoint will be evaluated at 6 months after treatment start, a one-stage phase ii study design was chosen. the unacceptable 6-month rate of progression free survival is 20% and the promising 6-month rate of progression free survival is 40%. 43 patients are to be treated. if ≤12 patients alive without progression at 6 months will be observed, the drug will be declared ineffective. if ≥13 patients alive without progression at 6 months will be observed, the drug will be declared promising. the α error rate (accepting a poor treatment) is 0.07 and the β error rate (rejecting a promising treatment) is 0.07. analysis of results will be separated between non acc and acc.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of recurrent and/or metastatic salivary glands (including acc and non acc). * progressive disease within 6 months before inclusion as assessed by ct and/or mri using at least two measurements (recist v1.0) with at least one measurable target lesion \>10 mm. * recurrent and/or metastatic salivary glands carcinoma failing locoregional therapy, without possibility of curative treatment. * patients may have had unlimited prior therapy but must have had at least 4 weeks between any chemotherapy, radiotherapy, surgery and study enrollment. * tumoral tissue must be provided for subsequent histological review and biomarker analysis. * euthyroid patient. * hepatic, renal, cardiac and hematology normal functions. * ability to take oral medication. exclusion criteria: * non salivary gland carcinoma (lachrymal gland tumor is excluded). * known or symptomatic cerebral metastasis. * patients treated with strong inhibitor or inductor of cyp3a4 within 14 days before inclusion. * presence of uncontrolled infection. * diagnosis of any previous malignancy within the last 5 years, except for completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma. * stable disease. * corrected qt interval (qtc) \>480 msecs using bazett's formula.
bryostatin 1 in treating patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of bryostatin 1 in treating patients with metastatic colorectal cancer.

objectives: i. determine the efficacy of bryostatin 1 administered as a 24 hour intravenous infusion every week for 3 weeks during a 4 week course of therapy in patients with colorectal cancer. ii. determine the response duration, time to progression, and survival time in this patient population. iii. determine the qualitative and quantitative toxic effects of bryostatin 1 on this schedule in this patient population. outline: patients are treated with bryostatin 1 as a 24 hour continuous intravenous infusion weekly for 3 weeks followed by 1 week of rest. courses are repeated every 4 weeks in the absence of unacceptable toxicity or disease progression. patients who have no toxic effects after the completion of the first course of therapy may have the dose of bryostatin 1 escalated by 1 dose level in subsequent courses. patients are followed for response duration and time to treatment failure. projected accrual: a total of 13-26 patients will be accrued for this study within 18 months.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed colorectal cancer unresectable disease measurable disease no uncontrolled brain metastases patient characteristics: age: any age performance status: swog 0-2 life expectancy: at least 12 weeks hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 times upper limit of normal (uln) ast no greater than 2.5 times uln renal: creatinine no greater than 1.5 times uln other: no active infection not pregnant or nursing negative pregnancy test for premenopausal women fertile patients must use effective contraception no concurrent uncontrolled systemic disorders no prior malignant disease within the past year except in situ carcinoma of the cervix or curatively treated basal cell carcinoma of the skin no history of allergy to bryostatin 1 or its vehicle prior concurrent therapy: biologic therapy: no concurrent immunotherapy chemotherapy: only one prior chemotherapy regimen in the adjuvant or metastatic setting allowed at least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) no other concurrent chemotherapy endocrine therapy: no concurrent hormonal therapy (except contraceptives, appetite stimulants and replacement steroids) radiotherapy: at least 3 weeks since prior radiotherapy no concurrent radiation therapy no concurrent palliative radiation therapy to only site of measurable disease surgery: not specified other: at least 1 month since prior use of any other investigational agent no concurrent use of experimental medications

Keywords: stage iv colon cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum
outpatient versus inpatient detoxification program for alcohol dependent patients seeking abstinence: the in/out study

Conditions: Alcoholism; Alcohol Dependence

Summary: detoxification, in an inpatient or outpatient program, is the primary and essential step for managing alcohol dependence. the superiority of one or other method of detoxification has never been proved in several previous randomized clinical trials (rct). the aim of this multicenter rct was to compare efficiency, on the abstinence rate as the primary outcome, at 1 and 3 months follow-up of two alcohol detoxification programs (a 5/7-days inpatient detox vs. an ambulatory detox).

among patients consulting in 4 alcohol treatment centers in france seeking treatment for withdrawal, we included those who met criteria for current alcohol-dependence (dsm iv) and having drinking during the past three days before randomization. exclusion criteria were: patients' refusal of one or other method, contraindication for outpatient detoxification method (history of delirium tremens or withdrawal seizures), homelessness, major depressive episode assessed by madrs \> 25, current substance abuse disorder (except nicotine), indication for hospitalization (severe somatic disorder), judicial injunction, family crisis, patients seeking antabuse treatment.

Eligibility criteria:
inclusion criteria: * alcohol dependence according to dsm iv * detoxification program requested by patients exclusion criteria: * refusal of the patient for the hospitalization or ambulant weaning alcoholic * contraindication in ambulant weaning * the state of the patient requires a hospitalization * ask of the patient for a treatment by the esperal

Keywords: alcoholism alcohol dependence detoxification abstinence maintain efficacy ambulatory detoxification
persistent pain and its impact on quality of life covid-19 patients that required critical care

Conditions: Chronic Pain; Post ICU Syndrome; Quality of Life

Summary: covid-19 infection produces thousands of hospital admissions in a very short period of time, including critical care patients. it is expected that those who survive a severe spectrum of the disease, will present some degree of health decline in the medium and long term, becoming chronic patients. post-intensive care syndrome (pics) was described by the society of critical care medicine (sccm) as a new altered or worsening of physical, cognitive, or mental condition due to critical illness and persisting after hospitalization, including pain. also, clinical features of infection include different types of pain, and if this pain persists, it can turn into a chronic condition. chronic pain is a currently recognized disease, but under-treated in many cases, generating a significant deterioration in the quality of life of this patient. it is vitally important to generate early care circuits to detect and treat those expected complications, such as chronic pain in these patients. the objective of this study is to estimate the level of persistent pain and its impact on health-related quality of life after admission to an intensive care unit in patients who suffered this infection.

the presence of persistent pain and impaired quality of life in covid19 patients who have required intensive care can affect up to a total of 50% of patients. main objective estimate the level of persistent pain and health-related quality of life after admission one in intensive care unit in covid-19 patients, a new disease that has been accompanied by great health, social and economic involvement from which we do not know the long-term consequences in this patient cohort. secondary goals * assessing patient's characteristics before icu admissión; the prevalence of painkillers use, including opioids, history of previous pain, and comorbidities. find relationships between these characteristics and the development of chronic pain. * determine if some icu treatments and patient's characteristics may contribute to persistent pain in covid-19 survivors ( number of prone therapies, thromboembolic complications, and medication for sedate used) * determine the quality of life using the sf-12 test. * determine pain characteristics using the id-pain test. * determine the scale of anxiety and depression using the hads test.

Eligibility criteria:
inclusion criteria: * post icu covid 19 survivor * adult 18 year or older, who gives its approval to participate exclusion criteria: * refusal to participate * neurological or physical secuale, disabled to answer a questionnaire